Elevance Health vs GSK

Elevance Health (ELV), health care, and GSK (GSK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

GSK is worth $99.1B on the stock market and Elevance Health $94.7B: GSK is valued at 5% more. Elevance Health trades at 18.6 times earnings and GSK at 17.2; operating margins in their latest fiscal years were 3.62% and 24.3%. Over the past year Elevance Health's share price has moved +37.5% and GSK's +6.42%.

Key facts

Elevance Health market value
$94.7B
GSK market value
$99.1B
Elevance Health P/E
18.6
GSK P/E
17.2
Elevance Health revenue
$199.1BFY to 2025-12-31
GSK revenue
$43.4BFY to 2025-12-31
Superinvestors holding both
3

Market values as of .

Elevance Health vs GSK: every measure side by side
Measure Elevance Health GSK
SectorHealth CareHealth Care
Country United States United Kingdom
Fiscal year ends2025-12-312025-12-31
Size
Market cap$94.7Blower$99.1Bhigher
Revenue$199.1Bhigher$43.4Blower
Earnings$5.7Blower$7.6Bhigher
Employees96,129higher66,841lower
Total assets$121.5Bhigher$81.1Blower
Valuation
P/E18.6higher17.2lower
P/S0.5lower2.3higher
P/B2.1—
Dividend yield1.54%—
Profitability
Operating margin3.62%lower24.3%higher
Balance sheet
Net assets$43.9Bhigher$21.7Blower
Total liabilities$77.5Bhigher$59.9Blower
Total debt$32Bhigher$19.2Blower
Cash on hand$9.5Bhigher$4.5Blower
Price change
Today-1.76%higher-1.90%lower
1 year+37.5%higher+6.42%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Elevance Health / GSK). Who owns ELV · Who owns GSK

Further comparisons

Learn

Questions and answers

Which is bigger, Elevance Health or GSK?

By market value, GSK is the larger: $99.1B against $94.7B for Elevance Health. By revenue in its latest fiscal year, Elevance Health is the larger: $199.1B against $43.4B for GSK.

Which has the higher P/E ratio?

Elevance Health: 18.6, against 17.2 for GSK. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

GSK: 24.3%, against 3.62% for Elevance Health. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Elevance Health: $32B, against $19.2B for GSK. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Elevance Health and GSK?

In their latest 13F filings, Jeremy Grantham (co-founder), Richard Pzena and Tweedy, Browne team hold both.

Cite this page

Funkfolio, “Elevance Health vs GSK”, data as of 17 November 2026. https://funkfolio.com/compare/elv-vs-gsk

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.